Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Isarna, Autotelic ink deal for Phase 3 compound
November 2015
SHARING OPTIONS:

MUNICH, Germany & FOUNTAIN VALLEY, Calif.—An asset sale and purchase agreement was announced mid-October between Isarna Therapeutics and Autotelic Inc. for trabedersen, Isarna’s TGF-ß2 (transforming growth factor beta 2) antisense oligonucleotide. Though no financial details were released for the deal, Autotelic will acquire full worldwide rights to develop trabedersen, which has reached Phase 3 clinical evaluation for the treatment of recurrent high-grade glioma.
 
“Autotelic Inc. has a unique expertise and resources that enables them to effectively advance trabedersen. The agreement, made possible by our partners at Egamid Ltd., recognizes our leadership in TGF-ß and our efforts to bring trabedersen to patients while allowing us to remain focused on our new generation of antisense oligonucleotides,” Dr. Philippe Calais, president and CEO of Isarna Therapeutics, remarked in a press release.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.